Elevance Health, Inc. Q2 FY26 Earnings Analysis

- Confident in at least 12% adjusted EPS growth in 2027, building from a baseline of $25.75 EPS in 2026 (Page 16). - Growth driven by margin expansion opportunities across most end markets and benefits from AI investments and prudent pricing strategies (Page 16). - Multiple independent earnings levers in motion since 2025, including pricing, care management, and portfolio positioning (Page 16). - Meaningful investments in 2026 expected to mature and boost returns in 2027 (Page 16). - Strong national account sales momentum, including marquee wins and nearly 100% renewals, supported by integrated medical and pharmacy capabilities (Pages 4, 5, 9). - Continued pipeline strength in employer markets and increasing consolidation of clients under single carrier arrangements (Pages 4, 9). - Medicaid membership declines expected to stabilize, with margin improvement anticipated in 2027 due to better rate alignment (Pages 6, 13). - AI-driven operational efficiencies and Carelon's risk-based integrated care expected to drive long-term growth (Pages 2, 16).

- Elevance Health expects at least 12% adjusted EPS growth in 2027 off a revised 2026 baseline of $25.75. - This growth is driven by margin expansion across most end markets and early benefits from AI and investment spend. - Key earnings levers already in motion include pricing discipline, care management, and portfolio positioning initiated in 2025 and 2026. - Meaningful investments made in 2026 are expected to mature and contribute to a clear step-up in returns in 2027. - The growth path relies on multiple independent levers across health benefits and Carelon, not a single assumption. - For 2026, the company raised its adjusted diluted EPS guidance to at least $26.75 based on strong Q1 results. - Medicaid margins are expected to remain pressured in 2026 but improve in 2027 due to better rate alignment.

- Elevance Health is investing more than $1 billion in digital and AI-enabled capabilities to support their strategy of improving affordability, simplifying healthcare, and personalizing member experience. - Investments are focused on embedding AI across clinical, operational, and administrative workflows to improve engagement, cost management, predictive analytics, and reduce administrative expenses through automation. - Meaningful investments are being made in 2026, expected to mature and deliver returns contributing to earnings growth in 2027. - Strategic investments support the scaling of Carelon’s risk-based solutions, including oncology, post-acute, and behavioral health programs. - Carelon’s integrated whole health approach combines CareBridge and Care at Home into a single risk-based solution driving better outcomes and cost savings. - Overall, investments are aligned with long-term durable financial performance and operational execution goals.

- The provided transcript pages do not mention any current or planned fundraising through debt or equity. - There is no discussion of issuing new shares beyond ongoing share repurchases (3.7 million shares repurchased for $1.1 billion in the quarter). - Capital deployment priorities focus on share repurchases and confidence in the long-term earnings power of the business. - No indication of issuing new debt or equity offerings was disclosed. - The company highlights operational execution, investment in AI and digital capabilities, and disciplined financial management. - No future fundraising plans via debt or equity are explicitly mentioned in this document.

The document does not explicitly provide a detailed current or expected order book or pending orders summary. However, related insights can be inferred: - Carelon Rx reports strong sales momentum, with total sales running ahead of plan for 2026 including two marquee national account wins. - Approximately 2 million members are in the queue for national business, with some related to second blue bid opportunities. - The national account pipeline for 2027 is described as very strong, nearly at a record level, reflecting positive demand in the employer and commercial markets. - Renewals in the national business are very high, with a renewal rate of about 99.3%. - The sales strength reflects employer focus on affordability, integrated medical and pharmacy models, and differentiated Carelon Rx value. No explicit numeric order book or pending orders figure is disclosed.